All In MedTech

Device Trial Radar · NCT07325461

Feasibility Study of Extended Wear Insulin Infusion Set Options During Home Use in People With Type 1 Diabetes

Last checked: Nov 19, 2026Latest source record: Aug 31, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

20

Actual

Start

Feb 18, 2026

Primary completion

Jun 24, 2026

Study completion Jun 24, 2026

Sponsor

Lead sponsor
Tandem Diabetes Care, Inc.Public (TNDM)
Sponsor type
Industry
First posted
Jan 8, 2026

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated device
Yes
Who can join
All sexes, from 18 years, up to 80 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This feasibility study is a prospective, single center, multi-arm study evaluating possible enhancements to the SteadiSet extended wear infusion set.

Conditions

  • Diabetes Mellitus, Type 1

Interventions

  • SteadiSet Infusion SetDevice

    Participants will use the SteadiSet Infusion set with an enhanced filling process for three wear periods and the Steadiset Infusion Set only for three wear periods.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. 7 Day Survival of Infusion Set for Primary Outcome MeasureTime frame: 6 weeks

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Stanford University

    Stanford, California

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.